Susan C. Guba

PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

Jyoti D. Patel, Mark A. Socinski, Edward B. Garon et al. · Journal of Clinical Oncology · 2013 · 374 citations · Full text

Medicine, Oncology, Pharmacology +13

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

Alba A. Brandes, Santosh Kesari, Juan Manuel Sepúlveda-Sánchez et al. · Neuro-Oncology · 2016 · 271 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer

Mark A. Socinski, Egbert F. Smit, Paul Lorigan et al. · Journal of Clinical Oncology · 2009 · 215 citations · Full text

Medicine, Oncology, Pharmacology +12

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

Davide Melisi, Do‐Youn Oh, Antoine Hollebecque et al. · Journal for ImmunoTherapy of Cancer · 2021 · 196 citations · Full text

Pharmacy, Oncology, Pharmacology +17

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

Ralph Zinner, Coleman K. Obasaju, David R. Spigel et al. · Journal of Thoracic Oncology · 2014 · 173 citations · Full text

Medicine, Oncology, Pharmacology +5